Abstract

The overall objective of this project is to conduct multidisciplinary collaborative clinical studies of therapeutic, pharmacologic, and toxicologic properties of various modalities including new chemotherapeutic agents and regimens, immunotherapy, radiotherapy, and surgery in the management of malignant diseases in humans. These collaborative studies are being performed in concert with the other institutional members and principal investigators who comprise the Southwest Oncology Group. Emphasis is placed on the multimodal approach to anti-cancer therapy whenever appropriate. These clinical research studies provide physicians with a background of experience and information which enables them to manage patients with malignant diseases more effectively.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA003096-30
Application #
3555724
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-01-01
Project End
1988-12-31
Budget Start
1987-01-01
Budget End
1988-12-31
Support Year
30
Fiscal Year
1987
Total Cost
Indirect Cost

  Institution

Name
University of Texas Medical Br Galveston
Department
Type
Schools of Medicine
DUNS #
041367053
City
Galveston
State
TX
Country
United States
Zip Code
77555

  Publications

Albain, Kathy S; Barlow, William E; Shak, Steven et al. (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65
Albain, Kathy S; Barlow, William E; Ravdin, Peter M et al. (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:2055-63
Moinpour, Carol M; Donaldson, Gary W; Nakamura, Yoshio (2009) Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial. Qual Life Res 18:147-55
Goodwin, J Wendall; Green, Stephanie J; Moinpour, Carol M et al. (2008) Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol 26:1650-6
Moinpour, Carol M; Donaldson, Gary W; Redman, Mary W (2007) Do general dimensions of quality of life add clinical value to symptom data? J Natl Cancer Inst Monogr :31-8
Agrawal, Amit; Moon, James; Davis, R Kim et al. (2007) Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in stage I, II, and III squamous cell carcinoma of the supraglottic larynx: report of Southwest Oncology Group Phase 2 Trial S9709. Arch Otolaryngol Head Neck Surg 133:1044-50
Petrylak, Daniel P; Ankerst, Donna Pauler; Jiang, Caroline S et al. (2006) Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98:516-21
Hesketh, Paul J; McCoy, Jason; Dunphy 2nd, Frank R et al. (2006) Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914. J Thorac Oncol 1:991-5
Smalley, Stephen R; Benedetti, Jacqueline K; Williamson, Stephen K et al. (2006) Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 24:3542-7
Leichman, Cynthia G; Benedetti, Jacqueline K; Zalupski, Mark M et al. (2005) Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study. Clin Colorectal Cancer 5:119-23

Showing the most recent 10 out of 41 publications